	LA CLUMATION NO.	
	Application No.	Applicant(s)
Notice of Allowability	09/729,658	ZONANA ET AL.
	Examiner	Art Unit
	Maria B. Marvich, PhD	1633
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this a or other appropriate communicati GHTS. This application is subject	application. If not included ion will be mailed in due course. THIS
1. This communication is responsive to <u>an after final amendm</u>	nent filed 5/9/06.	
2. The allowed claim(s) is/are <u>1,2,4,23-26,63,74 and 78</u> .		
3. Acknowledgment is made of a claim for foreign priority ur	nder 35 U.S.C. § 119(a)-(d) or (f).	
a) All b) Some* c) None of the:		
1. ☐ Certified copies of the priority documents have been received.		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		oly complying with the requirements
4. A SUBSTITUTE OATH OR DECLARATION must be subminification (PTO-152) which give		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date		e Office action of
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the		
6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT	sit of BIOLOGICAL MATERIAI FOR THE DEPOSIT OF BIOLOG	L must be submitted. Note the ICAL MATERIAL.
Attachment(c)		
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of Informa	I Patent Application (PTO-152)
2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summa	ırv (PTO-413).
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0	Paper No./Mail E 98), 7. ⊠ Examiner's Amen	Date ndment/Comment
Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit	8. Examiner's State	ment of Reasons for Allowance
of Biological Material	9. Other	
•		
		··

Application/Control Number: 09/729,658

Art Unit: 1633

ALLOWANCE

This office action is in response to an amendment filed 5/9/06. Claims 3, 5-22, 27-62, 64, 66-72, 75 and 77 have been cancelled. Claims 1, 24, 25, 73, 74 and 76 have been amended. Claim 78 has been added. Claims 1, 2, 4, 23-26, 63, 65, 73, 74, 76 and 78 are pending.

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Sheree Ryback on May 30, 2006.

The application has been amended as follows:

In the specification, replace the text on page 1, line 3-5 with the following –This application is a continuation-in–part application of U.S. Application No. 09/342,681, filed June 29, 1999, now US Patent No. 6,355,782, and claims priority from U.S. Provisional Applications 60/092,279 filed July 9, 1998 and 60/112,366 filed December 15, 1998--.

The claims have been amended as follows:

In claim 1, line 5 delete the phrase "an amino acid sequence having at least 95%

sequence identify to" following the phrase "wherein the EDA1-II protein comprises".

In claim 24, line 3, deleted the phrase "that enhances EDA1-II activity in the

subject" following the phrase "having at least 95% identity to SEQ ID NO:2".

Claim 25 (amended): The method of claim 1, wherein the amino acid sequence

EDA1-II protein comprises an amino acid sequence having at least 98% identity to SEQ

ID NO:2 that enhances EDA1-II activity in the subject.

In claim 26, line 1, the phrase "an amino acid" following the phrase "wherein the

amino acid sequence comprises" has been deleted and replaced with the word -- the--.

Claim 65 (canceled).

Claim 73 (canceled).

Claim 76 (canceled).

Conclusion

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Maria B. Marvich, PhD whose telephone number is (571)-

272-0774. The examiner can normally be reached on M-F (6:30-3:00).

Application/Control Number: 09/729,658 Page 4

Art Unit: 1633

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, David Nguyen, PhD can be reached on (571)-272-0731. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Maria B Marvich, PhD Examiner Art Unit 1633

May 31, 2006

DAVETRONG NGUYEN
SUPERVISORY PATENT EXAMINER